Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10964866 | Vaccine | 2015 | 5 Pages |
Abstract
These post-marketing surveillance data suggest a good safety profile for JE-VC consistent with findings from pre-licensure clinical trials. Post-licensure safety data should continue to be monitored for any evidence of rare serious or neurologic adverse events.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Ingrid B. Rabe, Elaine R. Miller, Marc Fischer, Susan L. Hills,